Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

Novartis' Cosentyx received FDA approval for polymyalgia rheumatica (PMR), its 11th US indication. The approval follows positive Phase III trial results showing sustained remission in PMR patients. Cosentyx is already approved for several immune-mediated diseases. Novartis plans to file for regulatory review in other countries, including Japan.

Original reporting
Published Nov 17, 2026, 2:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR) — source image
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

The FDA approval is a discrete regulatory milestone that can drive incremental expectations for Cosentyx’s immunology franchise, while the trial’s safety profile may influence near-term risk perception and uptake trajectory.

02

Market read

Traders can treat this as a new-indication regulatory catalyst for NVS, with immediate sentiment upside offset by attention to trial safety outcomes.

03

What to watch

Commercial impact will depend on how quickly PMR guidelines incorporate Cosentyx, real-world steroid taper feasibility, and whether post-marketing safety monitoring changes prescribing behavior.

Relevance 7/10Novelty 9/10Timing: FDA approval reported pre-market/early session (published 2026-11-17 02:43 UTC).

Background

Cosentyx (secukinumab) is already approved for multiple immune-mediated inflammatory diseases; this article adds a new US indication for polymyalgia rheumatica (PMR) based on the REPLENISH Phase III program.

Company-level read

Ticker impact

$NVSBullishMedium confidence
Context

Novartis’ Cosentyx received FDA approval as the first and only anti-IL-17 biologic for polymyalgia rheumatica, based on the REPLENISH Phase III trial.

Expected impact

Likely upward bias as the market prices in incremental revenue opportunity from a new indication, tempered by scrutiny of hypersensitivity, UTI, and rare fatal cryptococcal meningitis reported in the trial.

Evidence & confidence

The article is a direct regulatory approval for Cosentyx in PMR with efficacy and safety details, which is typically material for biotech/pharma sentiment and positioning.

Market effects

Reinforces anti-IL-17 biologics’ expanding rheumatology footprint, potentially increasing competitive focus on steroid-sparing strategies in PMR.

US label expansion can shift prescribing and payer discussions in the US; Japan filing noted as a follow-on regulatory step.

Global PMR treatment landscape may reprice as additional regulators consider similar data from REPLENISH.

Counterpoint

The approval is for a specific dosing arm (150 mg) with notable infection/hypersensitivity rates, so uptake may be slower than bulls expect due to clinician comfort and payer restrictions.

Key entities

  • Novartis

    Issuer of Cosentyx; received FDA approval for Cosentyx in PMR.

  • Cosentyx (secukinumab)

    Anti-IL-17A biologic; first and only FDA-approved anti-IL-17 biologic for PMR per the article.

  • REPLENISH trial (NCT05767034)

    Phase III study supporting the PMR approval; primary endpoint met at Week 52 after steroid taper.

Related articles

$NVSMed

Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica

Novartis announced FDA approval for Cosentyx (secukinumab) to treat polymyalgia rheumatica in adults unresponsive to corticosteroids. The 150-mg dose showed 40.5% remission at Week 52 vs. 20.5% for placebo. This is Cosentyx's 11th U.S. indication. The approval follows positive Phase III trial results, with the drug demonstrating steroid-sparing effects. Novartis also noted ongoing regulatory reviews in other regions.

$NVSMed

Novartis Pharma AG: Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

Novartis' Cosentyx (secukinumab) received FDA approval for treating polymyalgia rheumatica (PMR), marking its 11th US indication. The approval follows a Phase III trial where Cosentyx doubled sustained remission rates compared to placebo. Novartis aims to address the unmet needs of PMR patients, offering an alternative to long-term steroid use. The drug is already approved in the EU and under regulatory review in Japan.

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.